Navigation Links
Life Sciences Expert Navitas augments End-to-end Capabilities
Date:6/9/2017

PRINCETON, N.J. and DENMEAD, England, June 9, 2017 /PRNewswire/ -- Navitas, a technology-led Life Sciences services provider across Clinical, Regulatory and Safety, announced that it would be augmenting its capabilities with the niche expertise of its legacy brands - Ecron Acunova and Intelent, under the fold of its parent company TAKE Solutions. Navitas will now add to its IP and innovation intensive solutions with full-service CRO and Clinical & BA/BE capabilities, as well as Big Data Analytics expertise to emerge as an end-to-end strategic partner for Life Sciences companies to help them address their critical challenges and achieve their desired outcomes.

Ram Yeleswarapu, President & CEO, TAKE Solutions said, "We are proud to bring together our substantial and niche capabilities under the unified ambit of Navitas Life Sciences to present our client with truly transformational, flexible and adaptable end-to-end offerings. In addition to our technology driven offerings and insights derived from our world-class proprietary industry networks, our clients now also be able to benefit from the consolidated brand's proven clinical capabilities and trial experiences."

Krishnan Rajagopalan, Chief Growth Officer, Navitas Life Sciences said, "With this coming together of capabilities, Navitas Life Sciences is poised to offer its clients the best combination of industry expertise, data and analytics-driven insights and a motivated global team to deliver sustainable and valuable outcomes."

With this consolidation, Navitas' global footprint will cover the Americas, Europe and APAC.

Navitas Life Sciences

Navitas Life Sciences, a wholly owned subsidiary of TAKE Solutions, works as a strategic partner for large and mid-sized Life Sciences organizations to address critical challenges and achieve desired outcomes in Clinical, Regulatory and Safety. Navitas' technology-led Life Sciences services are augmented with the full-service CRO with Clinical & BA/BE capabilities, and Life Sciences data analytics expertise of legacy brands Ecron Acunova and Intelent to deliver flexible, scalable and innovative solutions for its global clients.

Navitas Life Sciences' expertise spans more than 1300 studies including BA/BE, NIS, and phase II – IV, and 70,000 regulatory submissions. The company's unique proprietary network forums that include 300+ professionals from 100+ life sciences companies generate insights that help members prepare for the future of the industry. Navitas Life Sciences seamlessly combining best-in-class processes, meaningful and unique industry insight, innovative technology, exacting analytics and a customer-centric culture. For more information, visit www.navitaslifesciences.com

About TAKE Solutions

TAKE Solutions is a globally recognized knowledge intensive player, delivering comprehensive and niche solutions in Life Sciences (LS). TAKE offers IP-based software and extensive knowledge-based solutions to enable efficient Clinical, Regulatory, Safety outcomes for global clients. TAKE encompasses specialized capabilities under its Life Sciences business Navitas, whose technology-led Life Sciences services across Clinical, Regulatory and Safety are augmented by full-service CRO with Clinical & BA/BE capabilities and Big Data analytics expertise of its legacy brands Ecron Acunova and Intelent. Navitas Life Sciences delivers flexible and scalable solutions by seamlessly combining best-in-class processes, meaningful and unique industry insight, innovative technology, exacting analytics and a customer-centric culture. 

TAKE's significant recognitions include a patent win from the United States Patent and Trademark Office (USPTO) for its 'Method for Optimizing Clinical Data Standardization', a 'Leader' certification in Drug Safety Services & Life Sciences R&D IT Outsourcing from IDC, recognition as the 'Dream Employer of the Year' at the World HRD Congress, the title of 'Most Admired Brand –IT' from the Asian Customer Engagement Forum and a Special Commendation for excellence in Corporate Governance from the Golden Peacock Awards. With its global headquarters in Chennai, India, TAKE has a proven track record of delivering world-class solutions to more than 400 customers worldwide, including 9 of the top 10 global Pharma companies. For more information, please visit www.takesolutions.com.   

Media contact:
Patrick Mullen
163519@email4pr.com 
609 454-7753

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/life-sciences-expert-navitas-augments-end-to-end-capabilities-300471044.html


'/>"/>
SOURCE Navitas Life Sciences
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Beckman Coulter Life Sciences to Showcase Analytical Methods to Measure Empty and Full AAV Particles
2. ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy
3. Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
4. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
5. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
6. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
7. USDM Life Sciences Names Holger Braemer, Vice President of EU and UK Division and Managing Director of USDM Europe GmbH in Germany
8. Navitas Life Sciences Augments Global Executive Management Team
9. Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares
10. Intec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman
11. EU Adopts New Diagnostics and Medical Device Regulations, USDM Life Sciences Helps Organizations Comply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives ... the award for Excellence in Volunteer Experience from US2020. , US2020’s mission is ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
Breaking Biology News(10 mins):